Does sorafenib modulate the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma?
This study provides evidence that the MDR phenotype of HCC cells can be modulated by the multi-kinase inhibitor sorafenib and consequentially may lead towards personalized therapies in patients with highly resistant tumors.
p27 expression predicts the clinical behavior of myxoid and round-cell liposarcomas, even in neoplasms with few or no round-cell differentiation.